“…Many NIR II OA/fluorescence probes, such as novel NIR II OA probes with DNA-based nanocarriers, PEGylated Au nanoparticles, and SPNs, that are of high chemical stability, low toxicity, and a high signal-to-noise ratio showed great promise for multimodal imaging and photothermal therapy ( Jin et al, 2010 ; Ding et al, 2019 ; Meng et al, 2019 ; Sun et al, 2019 ; Zhang et al, 2019c ; Feng et al, 2020 ; Xu et al, 2020 ; Joseph et al, 2021 ; Miyasato et al, 2021 ). - 5) Toward clinical translation: For fluorescence imaging, the U.S. Food and Drug Administration (FDA) approved several probes such as ICG ( Mokrousov et al, 2021 ), methylene blue, fluorescein, Prussian blue, 5-aminolevulinic acid ( Stummer et al, 2006 ), and Evans blue. A few fluorescence imaging contrast agents are in clinical trials at different 0stages including ONM-100 (pH-activable NP), second window ICG or SWIG, BLZ-100, Tumor Paint™, TumorGlow™, ABY-029, LUM015, SMG-101, OTL38, and Cornell dots ( Phillips et al, 2014 ; Whitley et al, 2016 ; Gutowski et al, 2017 ; Randall et al, 2019 ; Samkoe et al, 2019 ; Wahsner et al, 2019 ; Voskuil et al, 2020 ; Teng et al, 2021 ).
…”